Efficacy and Safety of Simultaneous Integrated Boost Radiotherapy in HR/VHR Prostate Cancer With EPLNI

The aim of this study is to evaluate the efficacy and safety of hypofractionated simultaneous integrated boost volumetric arc radiation therapy (SIB - VMAT) for high-risk and very high-risk localized prostate cancer in terms of: 1. Acute and late gastrointestinal and genitourinary toxicities. 2. Evaluate the efficacy in terms of early bPFS. 3. Dosimetric evaluation in terms of target coverage and organs at risk sparing

Trial Details

NCT ID
NCT07693075
Phase
PHASE2
Sponsor
Ain Shams University
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Simultaneous Integrated Boost Volumetric Modulated Arc Therapy (SIB-VMAT)
Locations (sample)
  • Cairo, Egypt|30.06263,31.24967
  • Shibīn al Kawm, Egypt|30.55258,31.00904
  • Sohag, Egypt|26.55695,31.69478

Key Eligibility Criteria

  • Histologically confirmed adenocarcinoma of the prostate.
  • Classification as High-Risk (HR) or Very High-Risk (VHR) per NCCN guidelines (e.g., T3a+, PSA \> 20 ng/mL, or Gleason Score 8-10).
  • Adequate baseline urinary function (IPSS \\le 20).
  • Multiparametric MRI of the prostate.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →